Evaluation of miR-210-3p contribution to the establishment and drug responsiveness of clear cell Renal Cell Carcinoma (ccRCC) and its relevance as potential biomarker for the metastatic progression.
| Componente | Categoria |
|---|---|
| Antonio Luigi Pastore | Componenti strutturati del gruppo di ricerca |
| Antonio Carbone | Componenti strutturati del gruppo di ricerca |
| Angelina Di Carlo | Componenti strutturati del gruppo di ricerca |
| Claudia Tito | Dottorando/Assegnista/Specializzando componente non strutturato del gruppo di ricerca |
| Componente | Qualifica | Struttura | Categoria |
|---|---|---|---|
| Natale Porta | Anatomo-Patologo | ICOT-Latina | Altro personale aggregato Sapienza o esterni, titolari di borse di studio di ricerca |
| Jessica Cacciotti | Tecnico Anatomo-Patologo | ICOT-Latina | Altro personale aggregato Sapienza o esterni, titolari di borse di studio di ricerca |
| Veronica Sorrentino | Tecnico Anatomo-Patologo | ICOT-Latina | Altro personale aggregato Sapienza o esterni, titolari di borse di studio di ricerca |
| Alessandro Ferrara | Tecnico Anatomia Patologica | ICOT Latina | Altro personale aggregato Sapienza o esterni, titolari di borse di studio di ricerca |
MicroRNAs (miRNAs) are emerging as promising molecules in the diagnosis, prognosis and treatment of urological tumours. Recently, our group performed two independent studies highlighting that miR-210-3p may represent a useful biomarker not only for diagnosis but also for post-surgery ccRCC management.
Starting from these results and with the aim to further assess the robustness of this miR-210-3p as a diagnostic and prognostic biomarker, we will analyze its levels in tissue, serum and urine specimens collected at surgery and during follow-up visits (from 3 to 12 months) from ccRCC disease-free patients and in patients presenting metastatic progression. Moreover, primary cell culture from tumor and metastatic tissues will be set up as relevant tool to explore the miR-210-3p contribution to ccRCC establishment and drug sensibility.
Research plan: i) evaluation of miR-210-3p expression levels in normal, primary tumor and metastatic tissues and in serum and urine collected at the day of surgery and during the follow-up of patients diagnosed with ccRCC, to clarify if clinical outcomes may correlate with its expression level; ii) evaluation of miR-210-3p contribution to ccRCC tumor phenotype and metastatic progression; iii) evaluation of the functional relevance of miR-210-3p in the response to conventional cytotoxic drugs treatments.
The comprehension of the contribution of miR-210-3p to ccRCC phenotype and metastatic progression may be relevant to pave the way for the identification and design of innovative clinical approaches in this tumor.